Skip to main content

Show 90 results Show all

Access Collaborative technical assistance (TA) resource menu

The Access Collaborative provides free data-driven technical assistance (TA), coordination, resources, and tools to ensure that women and girls have increased access to DMPA-SC and self-injection as part of an expanded range of contraceptive methods, delivered through informed choice programming.

In addition to general information and evidence on DMPA-SC, partners can access the support outlined in the menu below by submitting a request through the technical assistance request form, also linked below. Your request can be submitted by emailing the completed form to FPoptions@path.org.

Institutional author(s): PATH, Clinton Health Access Initiative (CHAI), Jhpiego, JSI, inSupply Health
Publication date: 2024

DMPA-SC Update newsletter

DMPA-SC Update is a periodic newsletter from the Injectables Access Collaborative highlighting global efforts to expand access to the self-injectable DMPA-SC in the context of a full range of family planning options. Click here to subscribe. For more information, please contact FPoptions@path.org.

Institutional author(s): PATH, Clinton Health Access Initiative (CHAI), inSupply Health, Jhpiego, JSI
Publication date: 2024

Policy brief template: Scaling-up self-injection of DMPA-SC to increase contraceptive access and options

This customizable DMPA-SC Advocacy Pack template provides a brief description of DMPA-SC; an overview of evidence on how the product expands access through multiple delivery channels; and policy and advocacy recommendations for country decision-makers.

Institutional author(s): PATH, Clinton Health Access Initiative (CHAI), inSupply Health, Jhpiego, JSI
Publication date: 2023

Balancing act: New developments and tensions in private sector access to DMPA-SC and self-injection

The Injectables Access Collaborative Learning and Action Network, in collaboration with USAID’s Frontier Health Markets Engage project, hosted this December 7, 2023 webinar on the latest innovations, policy developments, and evidence on access to DMPA-SC and self-injection through private sector channels such as pharmacies, drug shops, and private clinics.

One-third of contraceptive users in low- and middle-income countries access their method from a private sector source. Momentum is growing to ensure that contraceptive injectables, including DMPA-SC/self-injection, are among the range of methods offered through private channels. Speakers shared the latest evidence regarding pharmacy and drug shop provision of DMPA-SC/self-injection, updates on the release of a generic product, reflections on packaging for the private sector, and tensions between equity and financial sustainability in a changing landscape for contraceptive procurement financing. Speakers and participants discussed innovations to improve private sector channel economics and advance both equity and sustainability.

Institutional author(s): PATH, Clinton Health Access Initiative (CHAI), inSupply Health, Jhpiego, JSI, Frontier Health Markets Engage
Publication date: December, 2023

Injectables Market Assessment & Recommendations Summary

This healthy markets framework assessment highlights market opportunities for intramuscular (IM) and subcutaneous (SC) injectables and makes several recommendations on how to sustain and expand access.

The three primary takeaways from the assessment are:

  1. The lack of funding for procurement remains the main barrier to meeting global demand for injectables. This is also limiting demand across SRH products in general.
  2. IM injectables still dominate the injectables market. Shipments of SC injectables have been relatively modest over the last few years, with evidence of challenges to fulfill country orders. An increase is projected in the demand for SC injectables over time with secure, diversified supply, particularly if the price premium of SC versus that of IM injectables is reduced. The arrival of a generic SC injectable could make a significant difference when it comes to pricing, however uncertainties remain as to whether SC injectables will be able to fully realize their potential.
  3. Structural problems such as the lack of provider capacity and supportive policies to enable access are hindering the growth of the market for SC injectables and require special attention.

Institutional author(s): Shaping Equitable Market Access for Reproductive Health (SEMA Reproductive Health)
Publication date: July, 2023

Report

Measuring Scale-Up: A review of the AC sustainability tracking indicators

On March 21, 2023, the DMPA-SC Access Collaborative hosted this webinar highlighting the strengths and gaps of monitoring scale-up in the context of efforts to institutionalize DMPA-SC and self-injection in national family planning programs. The discussion focused on findings from Madagascar, Nigeria, Uganda, and Zambia, touching upon national goals for DMPA-SC, in-country perspectives on the value proposition of DMPA-SC, and suggested indicators for use in tracking the scale-up of a new product.

Institutional author(s): PATH, JSI
Publication date: March, 2023

Family Planning: A Global Handbook for Providers

The global family planning handbook provides high-quality, up-to-date guidance for health care professionals working in low- and middle-income countries. “Chapter 4: Progestin-Only Injectables” includes information and guidance for DMPA-SC administration and self-injection.

Institutional author(s): World Health Organization (WHO), Johns Hopkins Center for Communication Programs (JHU CCP)
Publication date: 2022

DMPA-SC and self-injection training materials

The Training Resource Package (TRP) for Family Planning’s Progestin-Only Injectable module includes sessions V and VI which are focused on DMPA-SC and self-injection, as well as a number of related handouts and resources. Developed in partnership with the Access Collaborative, these materials are intended for training health care providers who offer progestin-only injectable contraception (“injectables”) in the public or private sector.

The TRP website features training information and materials for a wide range of family planning methods. This includes curriculum components and tools for trainers to design, implement, and evaluate family planning and reproductive health training.

Institutional author(s): USAID, World Health Organization (WHO), UNFPA, PATH
Publication date: 2022

Excelerate your self-injection program data

An Excel skill-building workshop series

In March 2022, the DMPA-SC Access Collaborative Learning and Action Network (LAN) hosted an interactive skill-building workshop series on creating effective data visualizations to support family planning decision-making. This series was a hands-on skill-building opportunity using materials from the Access Collaborative’s Monitoring Learning and Evaluation (MLE) toolkit.

In this sequential series, each week’s session built upon the content of the previous session. For more information, please contact FPoptions@path.org.

Institutional author(s): PATH, JSI
Publication date: March, 2022

Web page Workshop page

Training supply recommendations for DMPA-SC rollout

DMPA-SC is a three-month injectable contraceptive that is easy to use and uniquely suited for self-injection. Demonstration and practice injections are a key part of training programs for both health workers and self-injection clients. Based on lessons learned in five countries, this memo summarizes PATH’s recommendations regarding devices for injection demonstration and practice, injection practice models, and waste disposal.

Institutional author(s): PATH
Publication date: 2022